Efficacy and safety of fruquintinib in the treatment of poor patients with metastatic gastrointestinal cancer.

Abstract

e16028 Background: To explore the efficacy and safety of fruquintinib in the treatment of poor PS patients with Metastatic colorectal cancer. Methods: The data of patients who were treated with fruquintinib in oncology department of our hospital from December 2018 to Janurary 2020 were analyzed retrospectively. Fruquintinib 5mg/ days, 3 weeks of withdrawal for 1 week, 4 weeks as a course of treatment, until the disease progression, death or voluntary cessation of treatment. When side effects occurred, the corresponding anti-symptomatic treatment can be given, if the drug side effects still intolerable, the drug was reduced to 4mg/ days or stop treatment. The adverse drug reactions were evaluated by CTCAE 4.0. The curative effects were evaluated by RECIST Version 1.1. All patients were followed up once every 28 days until the disease progression, death or voluntary cessation of treatment. Results: A total of 9 patients were included, including 2 patients with right metastatic colon cancer, 3 patients with advanced rectal cancer, the incidence of fruquintinib side effects was 100%, which occurred in the first 2 months of treatmentand was common in grade 1 and 2. The common symptoms were hypertension (100%),hand and foot skin reaction (50%), proteinuria (12.5%), dysphonia (31.4%), etc.Incidence of severe side effects was 12.5%, hypertension. Conclusions: The adverse reactions of fruquintinib often occurred within 2 months of treatment, most of which were grade 1 or 2; the patients can benefit from fruquintinib in physical state and organ function.